Company Description Adimab–which stands for Antibody Discovery Maturation Biomanufacturing–is developing a platform that’s deliberately engineered to minimize and potentially eliminate third party royalties, offering a one-stop-service-shop to a select few Big Pharma partners.
Proceeds Purposes Proceeds from the financing will be used to increase the capacity for conducting multiple parallel discovery programs as well as automating several aspects of our antibody discovery process.